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Introduction: Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by a homozygous
deletion of the survival motor neuron (SMN) 1 gene. Nusinersen is an antisense oligonucleotide
enhancing the production of the SMN protein. It has received approval by the European Medicines
Agency (EMA) in 2017, based on the clinical trials demonstrating the effectiveness of nusinersen in
several types of SMA. In Hungary, the first patient received nusinersen treatment in April 2018. Our aim
is to summarize our experience regarding the efficacy, safety and tolerability of nusinersen in our
patients.
Methods: Data were collected retrospectively in all types of SMA patients (type 1e3) starting treatment
with nusinersen in Hungary between April 2018 and December 2019. Motor functions were evaluated at
baseline, at the fourth and all following injections.
Results: By 31st December 2019, nusinersen therapy was initiated in 54 patients at either of the two
Hungarian treatment centres. Mean age of the patients at the start of the treatment was 6.3 years (±5,4
range 0.4e17.9). 13 patients are type 1 (mean 0.78 ± 0.27, range 0.4e1.5 yrs), 21 patients are type 2 (mean
4.5 ± 3.3, range 1.3e12 yrs), 23 patients are type 3 (mean 10.9 ± 5.2, range 2.9e17.9 yrs). Fourteen
patients had severe scoliosis, four of them underwent spine stabilizing surgery. During the study period
340 injections were administered without any new safety concerns emerging. The data of 38 patients,
who had completed the first six treatments, were included in the final statistical analysis. Motor function
has improved in most of the children. By the 307th day visit, on average, a 14.9 (±5,1) point improvement
was measured on the CHOP INTEND scale in type 1 patients (p ¼ 0.016). All patients with type 1 SMA
who performed the motor evaluation (7/10) have improved by more than four (7-21) points. Regarding
type 2 patients, a 7.2 (range -2- 17) point increase from baseline (p < 0.001) on the Hammersmith
Functional Motor Scale Expanded (HFMSE) and 4.3 (range: 2e9) point increase (p ¼ 0.031) on the
Revised Upper Limb Module (RULM) were found. The distance of the 6 min walk test also increased by
33.9 m on average (range -16 e 106), in type 3 patients.
Conclusion: According to our results nusinersen has the same safety and tolerability profile as in the
clinical trials. In a heterogenic patient population of SMA type 1 and 2, nusinersen showed similar ef-
ficacy as seen in the pivotal studies. A clinically and statistically significant improvement of motor
functions was also detectable in type 3 patients with heterogeneous age distribution.
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/)..hu (L. Szabo).
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L. Szabo et al. / European Journal of Paediatric Neurology 27 (2020) 37e4238disorder caused by a homozygous deletion in the survival motor
neuron (SMN) 1 gene on chromosome 5q13 [1,2], characterized by
progressive muscle atrophy and weakness, with an estimated
incidence of 1 in 7500 live births [3]. The disease severity of SMA is
strongly influenced by the copy number of the closely related SMN2
gene, which differs only in two exonic base pairs from the SMN1
gene [4,5]. Depending on the severity of symptoms, the highest
level of motor function (i.e. sitting or standing) and age of onset,
SMA is classified into five different subtypes (0e4). SMA 0 is the
most severe newborn form of the disease. Type 1 is the most
common (50e60%) subtype of SMA. Per definition, onset of
symptoms is before six months of age and the main cause of
mortality of these children is respiratory distress before two years
of age. Children with type 2 SMA are able to sit unassisted at some
point during their development; however they are never able to
walk independently. In type 3 SMA the symptoms occur after 18
months of age, and affected children are able to walk unassisted at
some point during their lifetime, but have a high risk of losing their
walking ability. Type 4 SMA is the least severe type; it occurs in
adult patients with diffuse symmetric proximal muscle weakness
and absent or markedly decreased deep tendon reflexes [6].
Nusinersen is the first disease modifying drug approved to treat
paediatric and adult patients with SMA [7]. Nusinersen is an anti-
sense oligonucleotide designed to modify the splicing behaviour of
the SMN2 gene thereby increasing the inclusion of exon7 and the
expression of full length SMN protein [8,9]. It was approved by the
US Food and Drug Administration in late December 2016 and by the
European Medicines Agency in June 2017 [10]. In Hungary, nusi-
nersen treatment is reimbursed by the National Health Insurance
Fund for all three paediatric types of SMA -with certain criteria-for
patients under 18 years of age, on a case-by-case basis.
Phase III double-blind placebo-controlled studies proved the
efficacy of nusinersen treatment in patients with SMA type 1 and 2
showing an improvement in motor milestones and event-free
survival [11,12]. Its efficacy in type 1 SMA population was also
demonstrated by the results of the Extended Access Programs (EAP)
[13e16]. There is limited data available on the therapeutic effect of
nusinersen in type 3 SMA patients [10,17].
2. Methods
We collected data retrospectively for all patients with SMAwho
received their first dose of nusinersen treatment in Hungary be-
tween April 2018 and December 2019. Based on the local admin-
istration criteria of nusinersen during our study period, patients
were not granted the therapy if a) they were over 18 month of age
(SMA types 1), b) they were over 18 years of age (SMA types 2, 3), c)
they performed below ten points in HFMSE (SMA types 2 and 3)
and d) if they needed permanent ventillation (defined as 16 h or
more on the ventilator per day; SMA types 1, 2 and 3). Patients were
assessed before administration of the first dose of nusinersen, at
the time of the 4th injection (63 days of treatment) and then every
four months prior to the administration of the next injection.
Before treatment initiation we collected data on clinical history,
SMN2 copy numbers and performed a full clinical examination
(including evaluation of nutritional, respiratory and body compo-
sition via DEXA (Dual Energy X-ray Absorptiometry) evaluation).
The patients were categorized into one of the three SMA types
based on the start of clinical symptoms and the best motor function
achieved. In case of discrepancy, decision was made based on the
best motor function. For evaluation of the motor function, the
Children's Hospital of Philadelphia Infant Test of Neuromuscular
Disorders (CHOP INTEND) was used in all patients younger than 2
years of age and in all non-sitter patients [11]. For patients who
were able to sit without assistance, the Hammersmith FunctionalMotor Scales Expanded (HFMSE) protocol was used with the
addition of the Revised Upper Limb Module (RULM) for those who
could sit by a table [12]. For walkers we performed the 6 Minute
Walk Test and HFMSE [18,19].
Changes over time were analysed with Wilcoxon matched pairs
signed rank test and linear regression analysis with GraphPad
Prism version 8.0.1 for Windows (GraphPad Software, San Diego,
California USA, www.graphpad.com) for all analysis. A p-value <
0.05 was considered as statistically significant difference.
The studywas approved by the Semmelweis University Regional
and Institutional Committee of Science and Research Ethics. (SE
RKEB 150/2019.). Parents were informed about the data collection
and gave written informed consent. We did not perform any pro-
cedures outside standard care.
3. Results
3.1. Demography
During the study period 57 patients started nusinersen treat-
ment in Hungary. Three of the patients (5.8%; all SMA I) were
excluded from the further analysis due to missing data: two of
them started the treatment in the Italian EAP and we could not
access the baseline motor functions, one other patient was initially
tested with HFMSE and no data on baseline CHOP INTEND was
available. Thirty-eight (66.7%) patients who completed the first six
treatments and had the assessments performed on Day 307 of the
treatment period were included in the final statistical analysis.
(Two of the type 1 patients included started their treatment in the
French and Belgian EAP) Table 1. shows the baseline characteristics
of all treated patients.
Fourteen patients had scoliosis, four of them underwent spine
stabilizing surgery (two Growing rod, one Magec, one other) prior
to the initiation of the tretment. One patient had percutaneous
gastrostomy tube and severe bulbar dysfunction with permanent
need of oral suction. All other children were able to feed orally.
Most of the children with type 2 and 3 SMA had annual
assessment of their lung function as a part of standard care of
neuromuscular patients in Hungary. Prior to or right after the
initiation of the treatment, all patients with type 1 and 2 SMA
underwent a complex respiratory assessment including poly-
somnography together with exhaled or transcutaneous CO2
monitoring. Based on this assessment, 18 children required assis-
tance with their breathing overnight in whom BiPAP therapy was
initiated. Themain indication of BiPAP therapy was hypoventilation
during sleep and subsequent hypercapnia during the night. All of
these patients were safe to be ventilated non-invasively and none
of them needed escalation of treatment (i.e. increasing BiPAP
pressures, tracheostomy and invasive ventilation) during the
period studied.
4. Motor function
4.1. SMA type 1
Motor function improved in all of the seven patients who per-
formed the motor evaluation at Day 307 and the improvement was
>4 points in each case. Detailed data are shown in Table 2. Change
from baseline became statistically significant at the time of the 5th
injection and remained significant by the time of the Day 307 visit.
At this time the average improvement was 14.9 points (±5.1, range
7e21) (Fig. 1). In this relatively small cohort we did not find cor-
relation between the age at treatment initiation and the degree of
improvement in motor function (Fig. 2) (p ¼ 0.559, R2 0.072,
Slope 0.417 (95% Confidence Intervals 2.13 to 1.3)
Table 1
Baseline demographics prior to treatment of all children including subgroups according to SMA types.
SMA 1 SMA 2 SMA 3 Total
N (% of total) 10 (18%) 21 (39%) 23 (43%) 54
Mean age (years) 0.78 4.5 10.9 6.3
(SD) (0.27) (3.3) (5.2) (5.4)
(min-max) (0.4e1.5) (1.3e12) (2.9e17.9) (0.4e17.9)
Median age (years) 0.8 2.9 13.1 5.26
Male/female 7/3 12/9 15/8 34/20
SMN2 copy number
2 copies 7 3 1 11
3 copies 3 18 12 33
4 copies 0 0 10 10
Follow up (days) (median) 473 (484) 415 (432) 370 (384) 408 (440)
Baseline motor function (min-max)
CHOP INTEND score 24.1 (2e43) e e
HFMSE score e 19.4 (2e33) 48.6 (27e64)
6MWT (m) e e 256.3 (24e426)
SMA: spinal muscular atrophy, SD: Standard Deviation, SMN: Survival of Motor Neuron, CHOP INTEND: Children's Hospital of Philadelphia Infant Test of Neuromuscular
Disorders, HFMSE: Hammersmith Functional Motor Scales Expanded, 6MWT: 6 Minute Walk Test. No patient had one copy of SMN2 gene.
Table 2
The average CHOP INTEND scores by the time points of the injections in SMA type 1 patients.
Time of evaluation (day) N CHOP INTEND Mean (SD) Change from baseline P value
Before treatment 7 30.0 (7.6) e e
63. 7 33.4 (8.6) 3.4 ns.
185. 7 39.0 (7.8) 9.0 0.016
307. 7 44.9 (6.7) 14.9 0.016
429. 6 47.8 (5.9) 20 0.031
551. 3 54.0 (5.3) 27.7 e
Fig. 1. The change from baseline in CHOP INTEND score in SMA type 1 patients.
Fig. 2. The relationship between the change from baseline in CHOP INTEND score and
the age at treatment initiation.
L. Szabo et al. / European Journal of Paediatric Neurology 27 (2020) 37e42 394.2. SMA type 2
Sixteen patients completed the follow up visit at Day 307. The
average motor performance measured by HFMSE improved
significantly at the 4th injection and the improvement remained
significant at all of the further evaluations. Detailed data are shown
in Table 3. At Day 307 of the treatment, average improvement was
7.2 points (±5.0, range -2-17) (Fig. 3). We found a statistically sig-
nificant correlation between the age at treatment initiation and the
change in HFMSE score at Day 307 of the treatment (p ¼ 0.008, R2
0.409, Slope0.984 (95% Confidence Intervals1.7 to0.31) in the
group of SMA type 2 patients. The earlier the treatment started, the
greater improvement was observed (Fig. 4). Upper extremity
function also improved significantly by 4.33 points on average(±2.78, p ¼ 0.031) by Day 307 and the improvement remained
stable at all consecutive assessments.
4.3. SMA type 3
Fifteenpatients completed the followupvisit atDay 307, ofwhom
12childrenwere ambulant. Averagemotorperformancemeasuredby
HFMSE improved significantly by 5.3 points (±4.4, range -1-13,
p¼0.001)by the timeof the6th injection (Fig. 5). Thedistancewalked
during the 6MWT improved in most of the patients, a significant in-
crease by 33.9 m was found at the 307th day of treatment
(±44.0range16.3e106.5m, p¼ 0.007). (Fig. 6). The age at treatment
initiation did not correlate significantly with either the change in the
HFMSE score (p ¼ 0.428, R2 0.092, Slope 0.270 (95% Confidence
Intervals 0.41 to 0.86), or the distance in 6MWT (p ¼ 0.465, R2
0.055, Slope 2.19 (95% Confidence Intervals4.25 to 8.64) at Day 307.
Table 3
The average HFMSE score by the time points of the injections in SMA type 2 patients.
Time of evaluation (day) N HFMSE Mean (SD) Change from baseline P value
Before treatment 15 21.2 (6.5) e e
63. 15 24.2 (9.2) 3.1 0.013
185. 15 25.9 (10.6) 4.0 0.021
307. 16 28.6 (9.7) 7.2 <0.001
429. 11 29.5 (11.4) 7.0 0.012
551. 7 26.1 (14.6) 5.7 Ns
Fig. 3. The change from baseline in HFMSE score in SMA type 2 patients.
Fig. 4. The change from baseline in HFMSE score and the age at treatment initiation in
type 2 SMA patients.
Fig. 5. The change from baseline in HFMSE score in SMA type 3 patients.
Fig. 6. The change from baseline in 6MWT in SMA type 3 patients.
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Lumbar punctures were performed without any severe com-
plications and nusinersen was administered intrathecal in all chil-
dren on all treatment days even in case of severe scoliosis.
Commonly used sedation procedure was N2O 50%; O2 50% gas
combined with a local anaesthetic agent. Occasionally we used
midazolam, ketamine or propofol for sedation in patients who
could not tolerate the mask or tube for gas administration. We
performed 340 injections during the observed period. The most
frequent side effects were the common symptoms of post-puncture
syndrome [headache (8%), backache (6%), vomiting (6%)]. Medical
conditions such as pneumonia, pneumothorax, bone fracture, leg
pain, transient andmild thrombocytopaenia, and UTI (Urinary Tract
Infection) were occasionally observed during the treatment period.From these conditions above thrombocytopaenia was reported af-
ter administration of some antisense oligonucleotides [20]. In our
study it only appeared in one patient on one occasion during the
treatment period and it was mild and transient. Although the role
of nusinersen cannot be ruled out in this condition; it is unlikely
that thrombocytopaenia in this case was related to the treatment.
No hydrocephalus or any other significant, drug specific side effects
were observed. No treatment was terminated because of side
effects.
5. Discussion
Our results show that nusinersen is a safe and effective treat-
ment in a heterogeneous population of children with SMA
throughout all ages and severity of the disease. After a one year
period we observed an improvement in motor function in most of
L. Szabo et al. / European Journal of Paediatric Neurology 27 (2020) 37e42 41our type 1, 2 and 3 SMA patients treated with nusinersen in a real
world setting in Hungary. These changes were not only statistically
significant but also clinically relevant for our patients who all re-
ported an improvement in their quality of life.
In the ENDEAR clinical trial a 71% responder rate (improvement
of >4 points in the CHOP INTEND score) was shown after 13months
of follow up in type 1 SMA patients [11]. The open label extension of
that clinical trial confirmed a 16.8 point average improvement on
the CHOP INTEND scale from baseline by Day 1058. Treatment
initiation before the age of 5.4 months resulted in an even greater
improvement of 19.3 points from baseline. However, a much
broader spectrum of type 1 SMA patients were treated with nusi-
nersen in the EAPs, where the authors described a similar, 42e77%
responder rate after a 6 month follow up period which seemed to
remain stable for 12 months [13e15]. Pane and colleagues found in
the Italian EAP that the improvement was most obvious in patients
younger than 7 months, however they also found improvement in
the older age group of SMA type1 patients [15]. Pechmann et al. also
found a greater change in CHOP INTEND score from baseline in
children aged 7 months compared to older children (children 7
months:14.4 ± 9.2; children>7months of age:7.0 ± 6.6). They
experienced slighter improvements in children requiring perma-
nent ventilation support or tracheostomy (change in CHOP INTEND
score was 5.6 ± 7.5) [13]. Aragon-Gawinska et al. described an
average of 3.5 points improvement in the CHOP INTEND score
among children between 8 and 111 months of age after a 6 months
follow up period [16]. In our cohort we started the treatment in all
children with SMA type 1 before the age of 1.5 years (mean
0.78 ± 0.27y). The average changes in CHOP INTEND score were
similar to younger patient group (14.9 ± 5.1 points) in the EAP, even
though the mean age at treatment initiation was higher (11 ± 4.4
months) in our cohort. We could not find a statistically significant
correlation between the age at treatment initiation and the efficacy
of treatment in the type 1 SMA population, most probably because
of the small number of patients in this group. All of our treated type
1 patients became responders by the time of the 6th injection. The
relatively good therapeutic response could indicate that age at
treatment initiation is an important factor of efficacy but not the
only one. Since patients with more than 16-hours of ventilation
dependency or with tracheostomy cannula were excluded from the
treatment according to the Hungarian reimbursement criteria, it is
possible that only less severe type 1 patients were alive and
without ventilation support and thus available for nusinersen
treatment at the time point of treatment initiation. This is also
indicated by the fact that the frequency of 3 copies of SMN2 gene in
the type 1 group is relatively high (30%). Data from patients,
including younger children with more severe symptoms, who
started the treatment right after their diagnosis and have not
completed the 6th injection yet, were not included in the current
statistical analysis. Based on our experience, we believe that the
baselinemotor function or the progression rate could also influence
the treatment outcome, as it was suggested by Pane at al. based on
the Italian EAP's data.
There is limited evidence to support the efficacy of nusinersen in
type 2 SMA patients beyond the RCT clinical study [10]. In the
CHERISH study, Mercuri et al. found an average of 4 points
improvement in HFMSE score after 15 months follow up in a cohort
involving 84 later onset SMA patients treated by 12 mg of nusi-
nersen. This study included children 2e12 years of agewith amotor
performance of 10e54 points in HFMSE [12]. The open label
extension of the CHERISH study (SHINE) involved 84 patients
treated with nusinersen previously and 42 patients who under-
went sham procedure. Patients treated with nusinersen from the
beginning, showed a 3.7 point improvement in HFMSE at the end of
the 1170 day follow up period [21]. A small number of type 2 SMApatients participated in the Phase I study (ISIS-SMNRx) but with a
wide age range from 2 to 14 years of age. In this dose-escalating
study, 7 patients received the 9 mg nusinersen dose that proved
to be effective. During the long term follow up the mean change of
HFMSE score was 5.8 points [22]. In our cohort, 7.2 (±5.0) point
improvement was experienced by the Day 307 visit. The better
results could be explained by the better adherence to care stan-
dards alongside the start of nusinersen treatment in the Hungarian
patient population.
In type 2 SMA patients, there is limited information available on
the factors influencing treatment effectiveness [12]. Our data sug-
gest a negative correlation between the age at treatment initiation
and treatment outcomes. As symptoms start between 6 and 18
months in type 2 SMA patients and therapy was started between
1.5 and 12 years of age, disease durationmight be a more important
factor beside the age itself. This hypothesis is also supported by the
fact that we could not find similar correlation between age and
efficacy in type 3 patients, in whom the age of the first symptoms
and the disease duration are not necessarily linked.
Efficacy of nusinersen treatment in type 3 SMA patients has
been suggested by phase 1e2 studies [22], however limited data
are available to describe the therapeutic response of this population
[10]. Montes et al. summarised patients’ follow up data who
participated the CS2 or CS12 open labelled clinical trials. Fourteen
subjects were ambulatory and performed the 6MWT during these
trials. Mean age at screening was 8.6 years. Median distance
measured at baseline was 250.5 m (range 0e563 m) and it
increased by 17 m range 47-99 m) at Day 253 and 99 m (range
31e150) at Day 1050 [17]. Based on Bohannon findings, a change of
14.0e30.5 m in 6MWT is clinically important across multiple pa-
tient groups [23]. Wurster at al. examining 11 type 3 SMA patients
between 13 and 60 years of age, could not find ameaningful change
in the HFMSE score at the time of the 4th injection [24]. By contrast,
in our cohort we found a meaningful increase in the 6 min walk
distance (33.9 m range -16-106 m) and a significant improvement
in the HFMSE score (mean 5.3, ±4.4, range -1-13 m) in type 3 SMA
patients.
6. Limitations
A longer, prospective follow up study with larger number of
patient would be necessary to confirm our findings. The clinical
protocol followed in the present study did not include the HINE-2
assessment, which could have reflected better the categorical
changes in type 1 cases. We measured only motor functions, but
additional use of patient reported outcome measures may reflect
better the impact of treatment on patients’ everyday lives. As
nusinersen is a splicingmodifier of SMN2 gene, copy number of this
gene is a possible influencer of treatment efficacy. However, we
could not study the impact of SMN2 gene copy number because of
the limited number of patients. Our cohort contains some patients
with discordant SMN2 copy number which also might have influ-
enced the treatment efficacy. Type 1 patient with three copies of
SMN2 gene may have better outcome. Patients with two SMN2
copies in type 2 or 3 SMA could carry a positive modifier [25,26]
which might also influence the outcome.
7. Conclusion
Our data suggest that nusinersen is an effective, life changing
treatment in children with a broad disease spectrum of SMA. The
drug can be administered intrathecal even in children with severe
scoliosis or following spine surgery. In the present study, no sig-
nificant drug-related side effects were observed over a year-period
of treatment and over the administration of 340 injections.
L. Szabo et al. / European Journal of Paediatric Neurology 27 (2020) 37e4242Importantly, there were no children missing a dose because of
technical difficulties at either of the two centres. Improvement in
the motor functions in patients with SMA is significantly related to
their quality of life; thus, further studies are required to establish
the long-term effects of nursinersen to optimize the therapy,
reduce the morbidity and mortality and hence improve the quality
of life of the patients.
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